• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Overall Survival Benefit with Sacituzumab Govitecan in Metastatic Breast Cancer: A Post Hoc Interaction Analyses of a Randomized Controlled Trail.

作者信息

Qiao Yu-Wei, Yu Guo, Li Guo-Fu

机构信息

School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, #24 Tongjia Lane, Nanjing, 210009, Jiangsu, China.

Institution of Drug Clinical Trial, Subei People's Hospital, Yangzhou, China.

出版信息

Clin Drug Investig. 2024 Jun;44(6):455-457. doi: 10.1007/s40261-024-01367-x. Epub 2024 Jun 5.

DOI:10.1007/s40261-024-01367-x
PMID:38837016
Abstract
摘要

相似文献

1
Overall Survival Benefit with Sacituzumab Govitecan in Metastatic Breast Cancer: A Post Hoc Interaction Analyses of a Randomized Controlled Trail.戈沙妥珠单抗治疗转移性乳腺癌的总生存获益：一项随机对照试验的事后交互分析
Clin Drug Investig. 2024 Jun;44(6):455-457. doi: 10.1007/s40261-024-01367-x. Epub 2024 Jun 5.
2
Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024 Jul 27;404(10450):338-339. doi: 10.1016/S0140-6736(24)01047-X.
3
Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024 Jul 27;404(10450):337-338. doi: 10.1016/S0140-6736(24)01045-6.
4
Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024 Jul 27;404(10450):339. doi: 10.1016/S0140-6736(24)01048-1.
5
Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024 Jul 27;404(10450):338. doi: 10.1016/S0140-6736(24)01046-8.
6
Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply.
Lancet. 2024 Jul 27;404(10450):339-340. doi: 10.1016/S0140-6736(24)01049-3.
7
Sacituzumab Govitecan: First Approval.Sacituzumab Govitecan：首次批准。
Drugs. 2020 Jul;80(10):1019-1025. doi: 10.1007/s40265-020-01337-5.
8
Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes.Sacituzumab govitecan 与化疗治疗转移性乳腺癌的安全性比较：一项荟萃分析。
Future Oncol. 2024;20(20):1427-1434. doi: 10.1080/14796694.2024.2354162. Epub 2024 Jun 12.
9
ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib.
ESMO Open. 2021 Feb;6(1):100018. doi: 10.1016/j.esmoop.2020.100018. Epub 2020 Dec 15.
10
Sacituzumab govitecan-hziy for triple-negative breast cancer.戈沙妥珠单抗-hziy用于三阴性乳腺癌
Lancet Oncol. 2019 Apr;20(4):e194. doi: 10.1016/S1470-2045(19)30074-9. Epub 2019 Feb 28.

本文引用的文献

1
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.在激素受体阳性和人表皮生长因子受体 2 阴性转移性乳腺癌（TROPiCS-02）中 sacituzumab govitecan 的总生存期：一项随机、开放标签、多中心、III 期临床试验。
Lancet. 2023 Oct 21;402(10411):1423-1433. doi: 10.1016/S0140-6736(23)01245-X. Epub 2023 Aug 23.
2
Informative Censoring of Progression-Free Survival Data in the TROPiCS-02 Trial: An Unrecognized Bias.TROPiCS-02试验中无进展生存期数据的信息性删失：一种未被认识到的偏倚
J Clin Oncol. 2023 Mar 10;41(8):1629-1630. doi: 10.1200/JCO.22.02234. Epub 2023 Jan 6.
3
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
Sacituzumab Govitecan 用于激素受体阳性/人表皮生长因子受体 2 阴性转移性乳腺癌。
J Clin Oncol. 2022 Oct 10;40(29):3365-3376. doi: 10.1200/JCO.22.01002. Epub 2022 Aug 26.
4
Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials.确证性临床试验中亚组分析的统计学考量教程。
Stat Med. 2017 Apr 15;36(8):1334-1360. doi: 10.1002/sim.7167. Epub 2016 Nov 28.
5
Biostatistics primer: what a clinician ought to know: subgroup analyses.生物统计学基础：临床医生应该了解的知识：亚组分析。
J Thorac Oncol. 2010 May;5(5):741-6. doi: 10.1097/JTO.0b013e3181d9009e.
6
Interaction revisited: the difference between two estimates.再谈交互作用：两个估计值之间的差异。
BMJ. 2003 Jan 25;326(7382):219. doi: 10.1136/bmj.326.7382.219.